Black Diamond Therapeutics Inc (BDTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.12+0.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BDTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.3% |
| Our one-year growth estimate | diamond | -91.1% |
Growth built into the price is above our model estimate.
The price assumes 3.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BDTX — earnings in line
Dated 2026-08-05
Results of Operations and Financial Condition. On August 5, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the six months ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”…
Why it matters: Starting this trial is key for expanding the use of silevertinib. It could open new markets if successful.
Supportive ifThe Phase 2 trial of silevertinib in GBM starts on schedule.
Worry ifThe trial start is delayed or canceled, showing possible problems with the drug.
Why it matters: A drop below this level may signal funding issues for operations into 2028.
Worry ifCash, cash equivalents, and investments are below $100 million.
Less concerning ifCash balance is above $100 million. This shows stable funding.
Why it matters: Watching expenses helps us see financial health and efficiency. Big changes could affect cash runway.
Watch forR&D expenses go down more, showing good cost control.
Also watch forR&D costs rise a lot, suggesting possible waste.
Why it matters: Updates on silevertinib's Phase 2 trial could impact its perceived value and market potential. Strong results could attract more investment.
Supportive ifGood results are shared from the Phase 2 trial of silevertinib for NSCLC.
Worry ifAnnouncement of disappointing results or failure to meet endpoints in the Phase 2 trial.
Why it matters: New results could show silevertinib works well for NSCLC. Strong results may help investor confidence.
Supportive ifPhase 2 trial results show a median progression-free survival (PFS) above 15.2 months.
Worry ifPhase 2 trial results show a median PFS below 15.2 months.
Why it matters: Updates on cash position will indicate if the company can fund operations into 2028. A strong cash position supports ongoing trials.
Watch forCash position remains above $100 million.
Also watch forCash position drops below $100 million.
Why it matters: Changes in R&D spending indicate how well the company is managing costs. Lower expenses could signal better financial health.
Watch forR&D expenses decrease below $7 million.
Also watch forR&D expenses increase above $8 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$227 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $747 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,694 loss on $10,000 · 66.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.